HK1099319A1 - Synthetic polysaccharide antigens for immunological intervention in disease - Google Patents

Synthetic polysaccharide antigens for immunological intervention in disease

Info

Publication number
HK1099319A1
HK1099319A1 HK07105329A HK07105329A HK1099319A1 HK 1099319 A1 HK1099319 A1 HK 1099319A1 HK 07105329 A HK07105329 A HK 07105329A HK 07105329 A HK07105329 A HK 07105329A HK 1099319 A1 HK1099319 A1 HK 1099319A1
Authority
HK
Hong Kong
Prior art keywords
disease
polysaccharide antigens
synthetic polysaccharide
immunological intervention
immunological
Prior art date
Application number
HK07105329A
Other languages
English (en)
Inventor
Larry Chris Blaszczak
John Astor Cleveland Jr
Kathleen Ann Taylor
Neil Thomas Blackburn
Angelika Regina Kraft
Charles Ellis Cohen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1099319A1 publication Critical patent/HK1099319A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK07105329A 2003-09-17 2007-05-21 Synthetic polysaccharide antigens for immunological intervention in disease HK1099319A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50378403P 2003-09-17 2003-09-17
PCT/US2004/026737 WO2005035588A1 (en) 2003-09-17 2004-09-15 Synthetic polysaccharide antigens for immunological intervention in disease

Publications (1)

Publication Number Publication Date
HK1099319A1 true HK1099319A1 (en) 2007-08-10

Family

ID=34434862

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07105329A HK1099319A1 (en) 2003-09-17 2007-05-21 Synthetic polysaccharide antigens for immunological intervention in disease

Country Status (9)

Country Link
US (1) US8129518B2 (ja)
EP (1) EP1664127A1 (ja)
JP (1) JP2007505905A (ja)
KR (1) KR100810770B1 (ja)
CN (1) CN100554279C (ja)
AU (1) AU2004280329B2 (ja)
CA (1) CA2538418A1 (ja)
HK (1) HK1099319A1 (ja)
WO (1) WO2005035588A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2407178A2 (en) 2005-04-19 2012-01-18 Eli Lilly and Company Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
JP2009537549A (ja) 2006-05-19 2009-10-29 トラスティーズ オブ ボストン ユニバーシティ 医療用潤滑剤およびゲルとしての新規の親水性ポリマー
US7850949B2 (en) 2006-09-29 2010-12-14 Michigan Technological University Purification of synthetic oligomers
US20090124573A1 (en) 2007-11-09 2009-05-14 Sarkis Mazmanian Immunomodulating compounds and related compositions and methods
FR2954703B1 (fr) * 2009-12-28 2013-12-13 Chu Nantes Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
ES2694100T3 (es) 2010-04-07 2018-12-18 California Institute Of Technology Vehículo para distribuir un compuesto en una membrana mucosa y composiciones, procedimientos y sistemas relacionados
US20110287048A1 (en) * 2010-05-20 2011-11-24 Round June L Antigen Specific Tregs and related compositions, methods and systems
WO2012047639A2 (en) 2010-09-27 2012-04-12 Michigan Technological University Purification of synthetic oligonucleotides
US9180173B2 (en) * 2013-12-09 2015-11-10 Stephanie D. Neider Methods of treating psoriasis using candida antigen
US10765696B2 (en) 2015-06-10 2020-09-08 City Of Hope Compositions of and methods of treatment with zwitterionic polysaccharide
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
BR112018070238A2 (pt) 2016-03-30 2019-01-29 Acib Gmbh detecção de infecção microbiana em feridas
EP3295926A1 (en) 2016-09-19 2018-03-21 Institut Univ. de Ciència i Tecnologia, S.A. Exopolysaccharide-protein complex, a method of preparing said complex and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186194A (en) * 1973-10-23 1980-01-29 Agence Nationale De Valorisation De La Recherche (Anvar) Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
SU727647A1 (ru) 1977-11-02 1980-04-15 Институт биоорганической химии им.М.М.Шемякина Гликопептиды,обладающие противоопухолевой активностью и способ их получени
US5834435A (en) * 1996-11-27 1998-11-10 Slesarev; Vladimir I. Inhibition of TNF-α pleiotropic and cytotoxic effects
US6955886B1 (en) * 1998-05-15 2005-10-18 Astrazeneca Ab Scintillation proximity assay for the detection of peptidoglycan synthesis
US20010034325A1 (en) * 2000-03-07 2001-10-25 Slesarev Vladimir I. Dietary modulators of gamma glutamyl transpeptidase
WO2001079242A2 (en) * 2000-04-18 2001-10-25 Eli Lilly And Company Process for preparing lipid ii and derivatives thereof
ATE374207T1 (de) * 2001-04-18 2007-10-15 Lilly Co Eli Verfahren zur herstellung von lipid ii
EP1494687A2 (en) * 2002-03-08 2005-01-12 Eli Lilly And Company Immunomodulatory polymeric antigens for treating inflammatory pathogies
US20040258779A1 (en) * 2003-06-06 2004-12-23 Pinegrin Boris V. Dietary and pharmaceutical compositions for treatment of anemia, thrombocytopenia, and leukopenia

Also Published As

Publication number Publication date
CA2538418A1 (en) 2005-04-21
CN100554279C (zh) 2009-10-28
US8129518B2 (en) 2012-03-06
KR20060057015A (ko) 2006-05-25
AU2004280329B2 (en) 2011-03-24
WO2005035588A1 (en) 2005-04-21
US20070041986A1 (en) 2007-02-22
AU2004280329A1 (en) 2005-04-21
KR100810770B1 (ko) 2008-03-07
JP2007505905A (ja) 2007-03-15
CN1867589A (zh) 2006-11-22
EP1664127A1 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
HK1099319A1 (en) Synthetic polysaccharide antigens for immunological intervention in disease
HK1195512A1 (zh) 多糖-蛋白軛合物疫苗
PT1599504E (pt) Anticorpo modificado
IL175710A0 (en) Anti-mpl antibody
TWI365883B (en) Antibodies to m-csf
GB0417384D0 (en) Antibodies to c-met
HK1096866A1 (en) Cancerous disease modifying antibodies
SG112929A1 (en) Single-crystal-silicon 3d micromirror
DK1228217T3 (da) Konserverede neisseria-antigener
EP1885755A4 (en) TREATMENTS OF AUTOIMMUNE DISEASES BY ANTI-CD19 ANTIBODIES
SI2374819T1 (sl) Protitelesa proteina MASP-2
EP1699487A4 (en) NEW ANTI-DC-SIGN ANTIBODIES
IL172242A0 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
EP1689781A4 (en) ANTIBODIES TO CD44 GLYCOFORMS AND ITS APPLICATIONS
EP1874343A4 (en) MONOVALENT AND MULTIPURPOSE SYNTHETIC POLYSACCHARIDIC ANATIGENS FOR IMMUNOLOGICAL INTERVENTION IN PATHOLOGY
AU2001264172A1 (en) Methods and compositions for diagnosing chronic immune disease
EP1718736A4 (en) ANTIBODIES MODIFYING EVOLUTION OF CANCER DISEASE
AU2003240822A8 (en) Antibodies that specifically bind to neurokinin b
EP1796721A4 (en) ANTIBODIES THAT MODIFY CANCER DISEASES
IL172511A0 (en) Specific human antibodies
EP1693386A4 (en) METHOD FOR THE PRODUCTION OF ANTIBODIES
EP1735432A4 (en) ANTIBODIES MODIFYING CANCER DISEASE
AU2003282241A8 (en) Antibodies for in vitro use
AU2002365187A8 (en) Epitope synchronization in antigen presenting cells
GB2411357B (en) Vaccine for cold-water disease in fish

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130915